Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 8.3
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Data is available to registered users only
Target Price
The average target price of STX.L is 13 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
